Schedule 13G ownership disclosure
Entrada Therapeutics Inc
COMMON STOCK · CUSIP: 29384C108
Event date: 2025-06-30
- Filing-level shares
- 2,567,478
- Percent of class
- 6.8%
- T. Rowe Price Associates, Inc.
Shares: 2,567,478 · Class: 6.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000080255-25-000607
- Form type
- SCHEDULE 13G/A
- Filer
- Entrada Therapeutics, Inc.
- CIK
- CIK 1689375
- Filed
- Aug 14, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership